Last reviewed · How we verify
administration of UIC202205, UIC202206
administration of UIC202205, UIC202206 is a Small molecule drug developed by Korea United Pharm. Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | administration of UIC202205, UIC202206 |
|---|---|
| Sponsor | Korea United Pharm. Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- administration of UIC202205, UIC202206 CI brief — competitive landscape report
- administration of UIC202205, UIC202206 updates RSS · CI watch RSS
- Korea United Pharm. Inc. portfolio CI
Frequently asked questions about administration of UIC202205, UIC202206
What is administration of UIC202205, UIC202206?
administration of UIC202205, UIC202206 is a Small molecule drug developed by Korea United Pharm. Inc..
Who makes administration of UIC202205, UIC202206?
administration of UIC202205, UIC202206 is developed by Korea United Pharm. Inc. (see full Korea United Pharm. Inc. pipeline at /company/korea-united-pharm-inc).
What development phase is administration of UIC202205, UIC202206 in?
administration of UIC202205, UIC202206 is in Phase 1.